Data Insights

GFH-018 by GenFleet Therapeutics (Shanghai) for Cervical Cancer: Likelihood of Approval

GFH-018 is under clinical development by GenFleet Therapeutics (Shanghai) and currently in Phase II for Cervical Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Cervical Cancer

Data Insights

GFH-018 by GenFleet Therapeutics (Shanghai) for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

GFH-018 is under clinical development by GenFleet Therapeutics (Shanghai) and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According...

Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Metastatic Hepatocellular Carcinoma (HCC)

Data Insights

GFH-018 by GenFleet Therapeutics (Shanghai) for Metastatic Pancreatic Cancer: Likelihood of Approval

GFH-018 is under clinical development by GenFleet Therapeutics (Shanghai) and currently in Phase II for Metastatic Pancreatic Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Metastatic Pancreatic Cancer

Data Insights

GFH-018 by GenFleet Therapeutics (Shanghai) for Solid Tumor: Likelihood of Approval

GFH-018 is under clinical development by GenFleet Therapeutics (Shanghai) and currently in Phase II for Solid Tumor. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Solid Tumor

Data Insights

GFH-018 by GenFleet Therapeutics (Shanghai) for Esophageal Cancer: Likelihood of Approval

GFH-018 is under clinical development by GenFleet Therapeutics (Shanghai) and currently in Phase II for Esophageal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Esophageal Cancer

Data Insights

GFH-018 by GenFleet Therapeutics (Shanghai) for Nasopharyngeal Cancer: Likelihood of Approval

GFH-018 is under clinical development by GenFleet Therapeutics (Shanghai) and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Nasopharyngeal Cancer

Data Insights

GFH-018 by GenFleet Therapeutics (Shanghai) for Metastatic Colorectal Cancer: Likelihood of Approval

GFH-018 is under clinical development by GenFleet Therapeutics (Shanghai) and currently in Phase II for Metastatic Colorectal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Metastatic Colorectal Cancer

Data Insights

GFH-018 by GenFleet Therapeutics (Shanghai) for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

GFH-018 is under clinical development by GenFleet Therapeutics (Shanghai) and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell...

Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

Data Insights

GFH-018 by GenFleet Therapeutics (Shanghai) for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

GFH-018 is under clinical development by GenFleet Therapeutics (Shanghai) and currently in Phase II for Head And Neck Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

GFH-018 by GenFleet Therapeutics (Shanghai) for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

GFH-018 is under clinical development by GenFleet Therapeutics (Shanghai) and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - GFH-018 in Bile Duct Cancer (Cholangiocarcinoma)